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Purpose: Our aim was to evaluate an optical coherence tomography (OCT) and visual acuity 
(VA)-guided, variable-dosing regimen with intravitreal ranibizumab injection for treating 
patients with neovascular age-related macular degeneration (AMD) from 2007 to 2012.
Design: This was a retrospective clinical study of 5 years follow-up in a tertiary eye center.
Patients and methods: In this study, 66 patients with neovascular AMD (mean age of 74 years, 
SD 8.7 years) were included. We investigated the development of best-corrected visual acuity 
(BCVA), the number of intravitreal injections, and the central retinal thickness measured with 
OCT (OCT Spectralis) over 5 years of intravitreal treatment.
Results: The mean number of intravitreal ranibizumab injections over 5 years was 8.8. The 
mean BCVA before therapy was 0.4 logarithm of the minimum angle of resolution (logMAR). 
After 5 years of therapy, the mean BCVA was 0.6 logMAR. In all, 16% of treated patients had 
stable VA over 5 years and 10% of study eyes approved their VA. The mean OCT-measured 
central retinal thickness at the beginning of this study was 295 µm; after 5 years of treatment, 
the mean central retinal thickness was 315 µm. There was an increase in central retinal thick-
ness in 47.5% of examined eyes.
Conclusion: Other studies showed VA improvement in OCT-guided variable-dosing regimens. 
Our study revealed a moderate decrease in VA after a total mean injection number as low as 
8.8 injections over 5 years. In OCT, an increase in central retinal thickness over 5 years could be 
observed. Probably, this is due to deficient treatment when comparing the total injection number 
to other treatment regimens. Anti-VEGF therapy helps to keep the VA stable for a period of 
time, but cannot totally stop the progression of the disease completely. Patients with late stages 
of neovascular AMD can maintain VA even if they are relatively undertreated.
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Introduction
Neovascular age-related macular degeneration (AMD) is a chronic, progressive disease 
that causes irreversible loss of vision among elderly people in developed countries.1 
Intravitreal anti-vascular endothelial growth factor (VEGF) therapy, the current 
standard for neovascular AMD, inhibits the progression of disease but does not seem 
to act on the causative mechanism underlying VEGF overexpression and the onset 
of active disease. It is unclear whether ocular anti-VEGF therapy leads to a cure and 
how many patients require long-term treatment for recurrent exudation.
Ocular anti-VEGF therapy has been widely used in clinical practice for many years. 
Ranibizumab (Lucentis; Genentech, Inc., South San Francisco, CA, USA) was approved 
in USA in June 2006. Even earlier than that, bevacizumab (Avastin; Genentech, Inc.) 
was described as an off-label ocular therapy.2 In Germany, three VEGF inhibitors 
were approved for the treatment of neovascular AMD: pegaptanib (Macugen; Pfizer, 
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Inc., New York, NY, USA), ranibizumab (Lucentis; Novartis 
International AG, Basel, Switzerland), and recently afliber-
cept (Eylea; Bayer AG, Leverkusen, Germany).
The aim of this study was to evaluate the effect of 
ranibizumab on patients with neovascular AMD under 
real-life conditions. It was a retrospective clinical study 
of 5 years follow-up in a tertiary eye center. We evaluated 
an optical coherence tomography (OCT) and visual acuity 
(VA)-guided, variable-dosing regimen with intravitreal 
ranibizumab injection for treating patients with neovascular 
AMD from 2007 to 2012.
Patients and methods
Study design
This was a retrospective clinical study of 5 years follow-up 
of a cohort of patients with neovascular AMD treated with 
ranibizumab in a tertiary eye center. The study was conducted 
in accordance with the tenets of the Declaration of Helsinki. 
The ethics committee of the University of Regensburg did 
not require that ethics approval and patient consent be sought 
and obtained for this study, due to its retrospective nature 
and because all data was de-identified.
Patients
In this study, 66 patients (39 females, 27 males) with neo-
vascular AMD (mean 74 years; SD 8.7 years) were studied. 
Only patients with a follow-up as long as 5 years were 
included in this study; there were no other inclusion criteria. 
In 14 patients, both eyes were treated. Neovascular AMD 
was diagnosed according to the following ophthalmologic 
diagnostic procedures: retinal examination by means of 
funduscopy, fluorescein angiography, and OCT.
Methods
OCT (OCT Spectralis; Heidelberg Instruments, Heidelberg, 
Germany) quantitative assessments were obtained using six 
diagonal fast scans. The central retinal thickness was mea-
sured as the distance between internal limiting membrane 
(inner boundary) and the retinal pigment epithelium, and 
the Bruch membrane (outer boundary). We used images 
where these boundaries were appropriately identified by the 
algorithm. We investigated the development of the retinal 
thickness during the treatment.
The mean VA was calculated arithmetically and on 
a logarithmic basis (a difference of 0.1 logarithm of the 
minimum angle of resolution [logMAR] level is equivalent 
to one early treatment diabetic retinopathy study [EDTRS] 
line or five letters).
The change in best-corrected visual acuity (BCVA) and 
in retinal thickness was analyzed using descriptive statistics 
(mean and standard error of mean). The total number of 
injections received by a patient was registered. Data from 
mean VA and mean retinal thickness after each year of therapy 
were statistically compared using the paired Student’s t-test. 
Statistical significance was defined as P,0.05.
Results
Baseline characteristics
Between 2007 and 2012, 66 patients (39 females, 27 males) 
with neovascular AMD were enrolled in this study. The 
mean age of these patients was 74 years (SD 8.7 years). All 
patients were Caucasians.
Our treatment regimen was based on European dosing 
recommendations with a loading phase of three injections. 
Retreatment was necessary in case of the following: visual 
loss of greater than five letters, a new hemorrhage, or a new 
lesion activity on fluorescence angiography. Additionally, 
an increase in retinal thickness of .100 µm measured by 
OCT was considered as an indication for retreatment. These 
therapeutic criteria were adopted from the prospective OCT 
study with Lucentis for neovascular AMD (PrONTO studies). 
PrONTO studies showed better results than the randomized 
double-masked, sham-controlled trial of ranibizumab for 
neovascular AMD (PIER study), which used a 3-month 
treatment regimen followed by ranibizumab injection every 
3 months.3–5 In our study, the mean number of intravitreal 
injections over 5 years was 8.8. There was a decrease in the 
number of intravitreal injections between 2008 and 2009 with 
a mean number of two injections per year. From 2009 to 2012, 
there was an increase in the number of intravitreal injections, 
which resulted in a stabilization of VA (Figure 1).
VA and OCT outcomes
After the first year of therapy, a significant improvement in 
VA was detected (P,0.01; Figure 2). This was associated 
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Figure 1 Increase in the number of injections per year from 2009 to 2012.
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with a significant decrease in the central retinal thickness 
measured by OCT (P,0.01; Figure 3). The mean central 
retinal thickness decreased by 37.8 µm, and the mean VA 
increased by 0.01 logMAR. In the following 2 years, there 
was a decrease in the number of intravitreal injections (mean 
number of injections in 2008 was 2.03; mean number of 
injections in 2009 was 2.1), which resulted in a significant 
decrease in BCVA (P,0.01) and an increase in central retinal 
thickness, which was not statistically significant (P.0.01). 
There was a correlation between the increase in central retinal 
thickness and the decrease in BCVA.
In the following 2 years, the number of intravitreal injec-
tions increased, which resulted in a significant increase in 
VA (P,0.01) and a corresponding decrease in central retinal 
thickness (P.0.01; Figures 2 and 3).
Over 5 years of follow-up, 16 patients (20%) had stable VA. 
In all, ten (12.5%) patients had improved VA and 54 (67.5%) 
had moderate VA loss. We detected a decrease in central retinal 
thickness in 37 (46.3%) eyes, a slight increase in central reti-
nal thickness in 38 (47.5%) eyes, and there was no difference 
between the central retinal thickness measured by OCT in the 
beginning and in the end of this study in one (1.3%) eye.
Discussion
The present retrospective study of 66 patients observed 
the treatment of neovascular AMD with ranibizumab 
under real-life conditions. The patients got a total mean 
of 8.8 injections during a period of 5 years. In previous 
randomized clinical trials, the number of intravitreal injec-
tions received by patients was higher. The mean number of 
ranibizumab injections during 2 years of treatment in the 
ranibizumab versus verteporfin photodynamic therapy for 
neovascular AMD study (ANCOR study) was 21.3.6 The 
patients in the CATT study (ranibizumab and bevacizumab 
for neovascular AMD) were treated with a mean of seven 
additional injections during the first year.7 The patients who 
finished the HORIZON study were treated in the SEVEN-UP 
study. In this study the patients got a mean number of 6.8 
injections per year for a period of 3.4 years, with a total mean 
of 23.12 injections per person for this period.8
The striking differences in retreatment numbers show that 
therapy in a daily routine may differ significantly from that 
in controlled clinical trials. The COMPASS study (efficacy 
of treatment with ranibizumab in patients with wet AMD 
in routine clinical care), another multicentre prospective, 
non-interventional study, also showed an undertreatment 
of patients with neovascular AMD. Patients received a total 
mean of 4.5 injections: three injections during upload phase 
and 1.5 additional injections during the maintenance phase 
of 12 months.9 It also showed that under real-life conditions, 
a considerably lower number of patients received the number 
of injections required to improve or maintain VA during the 
maintenance phase using previously recommended retreat-
ment criteria.
Probably, the criteria from the PrONTO study are too 
broad for an individual effective treatment of recurrence of 
neovascular AMD under a routine clinical setting. In uncon-
trolled, retrospective analyses, it was shown that a pro re nata 
(PRN) regimen with fewer than five injections in the first year 
was not able to achieve VA improvement.10,11 This treatment 
strategy was based on mathematical drug and disease model 
recommending 8.1 injections to be needed in the first year of 
treatment.12 Under routine clinical conditions, it seems that 
these retreatment criteria are not sufficient enough to detect 
recurrence and VA did not achieve the levels expected in 
other clinical trials.13 A systematic review of as needed versus 
treat and extend anti-VEGF treatment regimens compared 
eight studies meeting treat and extend protocol and 62 studies 
meeting PRN protocol. The treat and extend group received 
an average of 8.09 injections at the first year compared to 
the PRN group who received a mean of 5.6 injections. The 
mean improvement in VA in the treat and extend group was 
10.4 ETDRS letters compared to 5.4 ETDRS letters in the 
PRN group. The study suggested superiority of the treat and 
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Figure 2 Development of BCVA during therapy.
Abbreviations: BCVA, best-corrected visual acuity; logMAR, logarithm of the 
minimum angle of resolution.
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Figure 3 Development of central retinal thickness during therapy.
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extend treatment to PRN regimen in a 12-month period.14 
Randomized clinical trials should be done to evaluate long-
term efficacy outcomes with these regimens.
One reason for the moderate decrease in VA in the present 
study might be the fact that decimal VA testing was used. 
This standard VA testing is probably not sensitive enough to 
detect recurrence sufficiently early. Most controlled clinical 
studies use ETDRS charts, which are more sensitive for the 
development of VA. The same reason for poor VA outcome 
is suggested in the COMPASS study, which used Snellen 
VA testing.9
Therefore, in our study, OCT data were included to assess 
the necessity of retreatment. OCT retreatment criteria were 
based on the recommendations of the German ophthalmologi-
cal societies (German Ophthalmological Society, Association 
of Ophthalmologists, and Retina Society). They advise the 
implementation of morphologic criteria for reinjection (new 
hemorrhage or morphologic criteria on OCT).3
Despite these established retreatment criteria, our study 
showed a moderate decline in BCVA over 5 years. The 
possible reasons are the irregular visits of our patients and 
the poor response to treatment of some patients. Surprisingly, 
despite these restrictions, VA remained on a stable low level, 
which shows that also a low number of intravitreal injections 
can help to prevent greater visual loss and a stabilization of 
VA in AMD patients.
The authors of the COMPASS study consider that 
patients receiving up to seven injections of ranibizumab 
during a follow-up period of 15 months displayed the best 
visual outcomes, which is similar to the finding from the 
CATT study.7,9 Patients receiving more than five additional 
injections at 15 months did not improve in VA compared to 
those receiving four additional injections. In another study 
by Heimes et al,15 it was reported that flexible, VA-driven 
ranibizumab retreatment regimen, used in clinical practice 
in Germany, generally results in a decline in BCVA during 
the 12 months of follow-up.
The mean number of intravitreal injections during the 
first year of follow-up was as low as 3.03, which is signifi-
cantly below the number of injections in other studies and 
clearly below the expected number of injections to maintain 
VA. There was an increase in the number of intravitreal 
injections up to 3.93 in the last 2 years of follow-up. The 
reason for the increase in injections in the last years of the 
study is probably the fact that during this period, ranibi-
zumab treatment was established in Germany and both 
clinicians as well as patients gained more experience in 
treatment modalities. Notably, because of the increase in 
the number of intravitreal injections during the last years 
of observation, VA and central retinal thickness remained 
stable over this period.
Conclusion
Studies such as MARINA, ANCHOR, and CATT showed VA 
improvement in OCT-guided variable-dosing regimens with 
a high number of intravitreal injections. Our study revealed 
a moderate loss in VA and a slight increase in central retinal 
thickness during a 5-year follow-up of patients with neovas-
cular AMD with a mean injection number as low as 8.8. The 
overall treatment success was below that shown in controlled 
clinical trials. These are results of a deficient treatment.
In particular, elderly patients were not able to travel long 
distances often for regular visits in our clinic. Furthermore, 
many patients suffered from later stages of AMD (initial 
BCVA 0.4 logMAR). It seems that under real-life conditions, 
recurrences and the need for retreatment are detected later 
than in controlled clinical trials.
Anti-VEGF therapy helps to stabilize VA and to prevent 
greater loss of vision, but cannot completely stop the progress 
of the disease.
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